Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.

doi:10.1038/s41416-024-02834-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.

British journal of cancer - 1 Oct 2024

Sudo Kentaro, Nakamura Yoshiaki, Ueno Makoto, Furukawa Masayuki, Mizuno Nobumasa, Kawamoto Yasuyuki, Okano Naohiro, Umemoto Kumiko, Asagi Akinori, Ozaka Masato, Ohtsubo Koushiro, Shimizu Satoshi, Matsuhashi Nobuhisa, Itoh Shinji, Matsumoto Toshihiko, Satoh Taroh, Okuyama Hiroyuki, Goto Masahiro, Hasegawa Hiroko, Yamamoto Yoshiyuki, Odegaard Justin I, Bando Hideaki, Yoshino Takayuki, Ikeda Masafumi, Morizane Chigusa

Abstract excerpt

BACKGROUND: Identification of homologous recombination deficiency (HRD) remains a challenge in advanced pancreatic cancer (APC). We investigated the utility of circulating tumour DNA (ctDNA) profiling in the assessment of BRCA1/2 and ATM mutation status and treatment selection in APC. METHODS: We analysed clinical and ctDNA data of 702 patients with APC enroled in GOZILA, a ctDNA profiling study using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxia Telangiectasia Mutated Proteins

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Circulating Tumor DNA

Share to Deoxycytidine

Share to Gemcitabine

Share to Paclitaxel

Source

Open in PubMed Open full text

Identifiers

PMID: 39198618
DOI: 10.1038/s41416-024-02834-0
PMCID: PMC11443054

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.PMID 39198618Read ↗

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialSemantic proximity Read ↗

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.Semantic proximity Read ↗

Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.Semantic proximity Read ↗

Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.Semantic proximity Read ↗

Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.Semantic proximity Read ↗

Germline mutations in pancreatic cancer and potential new therapeutic optionsSemantic proximity Read ↗

Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.